The future of immunotherapies in the CTCL treatment landscape

Due to the chronic nature of CTCL, chemotherapy is not a suitable option for patients. Francine Foss, MD, Yale University School of Medicine, New Haven, CT, describes potential non-chemotherapy treatment options for patients with cutaneous T-cell lymphoma (CTCL). Monoclonal antibodies such as the anti-CC chemokine receptor 4 (CCR4) mogamulizumab have proven to be more efficacious than vorinostat and is easier to administer, especially in the backdrop of the COVID-19 pandemic. Chimeric antigen receptor (CAR) T-cell therapies such as ones that target CD17 and CD30 additionally represent a new class of promising therapies for patients with CTCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.